Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSION: Sequential XELIRI/XELOX + Bevacizumab in mCRC
NCT02119026Phase 2Completed
- Start
- Feb 2011
- Primary completion
- Aug 2017
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, capecitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in metastatic colorectal cancer (mCRC). Started Feb 2011; status: completed.
02
Drugs
bevacizumabcapecitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02119026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119026.